Čeština | Dansk | Deutsch | English | Español | Français | Italiano | Nederlands | Norsk | Polski | Português | Pусский | Suomi | Svenska | US
Euro Huntington's disease network [logo]
EHDN2018 DISEASE NETWORK REGISTRY PROJECTS LOGIN
 
 
  
EHDN2012 - Documents - Presentations -
--->Nyheter
[-]Projektet
--->Sponsor
--->[+]Verkställande kommitté
--->[+]Writing Committee Strategic ...
--->[-]Vetenskaplig granskningskom...
--->Offentlige Dokument
--->Centralkoordination
--->Språkkoordination
--->Fellowship Programme
--->[+]Constitution
--->[-]Medlemmar
--->Request
[-]Studiesajter
--->[+]Österrike
--->[+]Belgien
--->[-]Tjeckiska republiken
--->[+]Coordination
--->[+]HD Associations
--->Brno
--->Ostrava
--->Olomouc
--->Prague
--->[+]Danmark
--->[+]Finland
--->[+]Frankrike
--->[+]Tyskland
--->[+]Ireland
--->[+]Italien
--->[+]Nederländerna
--->[+]Norge
--->[+]Polen
--->[+]Portugal
--->[+]Russia
--->[-]Spanien
--->Coordination
--->HD Associations
--->Alicante
--->Badajoz
--->Barcelona - Bellvitge
--->Barcelona - Clinic i Provincia...
--->Barcelona - Mutua de Terra...
--->Barcelona - Santa Creu i Sa...
--->Barcelona - Merced
--->Bilbao
--->Burgos
--->Canaries
--->Granada
--->Fuenlabrada
--->[+]Madrid-BTCIEN
--->Madrid - Clínico
--->Madrid - FJD
--->Madrid - RyC
--->Murcia
--->Oviedo
--->Palma de Mallorca
--->Pamplona
--->Santiago
--->Sevilla
--->Sevilla-HUVRocio
--->Sevilla-St-Ana
--->Valencia
--->Zaragoza
--->[+]Sverige
--->[+]Schweiz
--->[+]Storbritannien
--->[-]Outside Europe
--->[+]Seoul
--->[+]Singapore
--->Sydney
[-]Arbetsgrupper
--->[+]Advanced HD
--->[+]Behavioural Phenotype
--->[+]Biological Modifiers
--->[+]Biomarkers
--->[+]Brain and Tissue Banking
--->[-]Cognitive Phenotype
--->[-]Dates
--->[-]Meetings
--->Meeting 2005/03
--->Meeting 2008/09
--->Meeting 2009
--->Meeting 2012
--->[+]Environmental Modifiers
--->[+]Functional Ability
--->[+]Genetic Testing
--->[-]Genetic Modifiers
--->[+]Dates
--->[-]Meetings
--->Meeting 2005/09
--->Meeting 2006/04
--->Meeting 2008/09
--->Meeting 2009/06
--->Meeting 2012/13
--->[+]Health Economics
--->[+]Imaging
--->[+]Juvenile HD
--->[+]Motor Phenotype
--->[+]Neuroprotective Therapy
--->[+]Physiotherapy
--->[-]Quality of Life
--->[+]Dates
--->[-]Meetings
--->Meeting 2005/03
--->Meeting 2005/09
--->Meeting 2006/07
--->Meeting 2006/12
--->Meeting 2007/09
--->Meeting 2008/08
--->Meeting 2008/09
--->Meeting 2009/11
--->Meeting 2010/05
--->Meeting 2016/09
--->Meeting 2017/07
--->[-]Standard of Care
--->[-]Dates
--->[+]Meetings
--->[+]Dieticians
--->[+]SALT
--->[+]Dental care
--->[+]Occupational
--->[+]Surgical Approaches
--->[+]Symptomatic Research
--->[+]Young Adults
[-]Events
--->[-]EHDN 2018
--->Announcement
--->Introduction
--->Programme Fri
--->Programme Sat
--->Programme Sun
--->Additional Meetings
--->Registration
--->Photos
--->Sponsoring/Partners
--->CME points
--->HD on the Move
--->Travel Information
--->Hotel booking
--->Flight booking
--->ACV Security Checks
--->About Vienna
--->Useful information
--->Contacts
--->Reimbursement
--->[+]Abstract Submission
--->Documents
--->Feedback
--->[+]EHDN 2016
--->EHDN 2014
--->[-]EHDN 2012
--->Introduction
--->Announcement
--->Programme Fri
--->Programme Sat
--->Programme Sun
--->Additional Meetings
--->Important Dates
--->Registration
--->[+]Travel & Accommodation
--->[+]EHA Registration
--->EHA Programme
--->Reception Dinner
--->About Stockholm
--->[+]Abstract Submission
--->Reimbursement
--->[-]Documents
--->Handouts
--->Presentations
--->[-]Posters
--->Pathogenic mechanisms
--->Animal models
--->Choreatic disorders - no...
--->Genetic modifiers
--->Wet Biomarkers
--->Imaging
--->Clin characteristics
--->Clin char-motor
--->Clin char-cognitive
--->Clin char - behaviour
--->Clin char-other
--->Clinical studies
--->Genetic testing
--->Clinical care
--->Experimental Rx
--->Clinical Rx
--->Non-scientific
--->Contacts
--->Feedback & Evaluation
--->[+]EHDN 2010
--->[-]EHDN 2008
--->Programme
--->Additional Meetings
--->EHA Programme
--->Social Programme
--->Kids Programme
--->Important Dates
--->Voting
--->Reimbursement
--->[+]Registration
--->[-]Abstract Submission
--->Evaluation & Feedback
--->[+]Travel and Location
--->[+]About Lisbon
--->[-]Documents
--->EHA
--->Committees
--->Contact
--->[-]EHDN 2007
--->Final Programme
--->Additional Meetings
--->Meeting Venue
--->[-]About Dresden
--->Cultural Entertainment
--->Sightseeing
--->Food & Drink
--->[-]EHDN 2006
--->Introduction
--->Final Programme
--->Plenary Dinner
--->Meeting Venue
--->[-]About Blankenberge
--->Cultural Entertainment
--->Sightseeing
--->Food & Drink
--->[-]EHDN 2005
--->Final Programme
--->Plenary Dinner
--->Registration
--->Working Groups
--->Meeting Venue
--->Manchester
--->Evaluation & Feedback
--->[+]EHDN 2004
[-]Kommunikation
--->Kontaktformulär
--->Chattrum
--->Adressregister - offentlig
--->Newsletter
--->Job Offers
datumbeskrivningstorlekförfattare dokument 
11.04.13Plenary Session I: ‘A look ahead’33blankintext/x-cms-notePlenary-Session-I 
11.04.13Frequency of Huntington Disease - Greater than you think9 kBblankinapplication/pdfehdn-2012-hayden-empty-file 
11.04.13What are we really looking for in an HD drug?9 kBblankinapplication/pdfehdn-2012-sampaio-empty-file 
11.04.13Care, coping and research in HD – the earlier the better!9 kBblankinapplication/pdfehdn-2012-duerr-empty-file 
11.04.13Plenary Session II: ‘Frontiers in biology and their relevance to Huntington’s disease’ 33blankintext/x-cms-notePlenary-Session-II 
11.04.13Longevity pathways and their relevance to human disease9 kBblankinapplication/pdfehdn-2012--aguilaniu-empty-file 
11.04.13RNA toxicity in poly-Q disorders3.3 MBblankinapplication/pdfehdn-2012-krzyzosiak 
11.04.13Post-translational modifications and proteolysis of huntingtin9 kBblankinapplication/pdfehdn-2012-truant-empty-file 
11.04.13Plenary Session III: ‘Science practice at EHDN’ 33blankintext/x-cms-notePlenary-Session-III 
11.04.13Scientific strategy of EHDN126 kBblankinapplication/pdfehdn-2012-bronzova 
11.04.13Juvenile HD Working Group441 kBblankinapplication/pdfehdn-2012-quarrell 
11.04.13Advanced HD Working Group9 kBblankinapplication/pdfehdn-2012-youssov-empty-file 
11.04.13Animal studies on the effects of physiotherapy9 kBblankinapplication/pdfehdn-2012-brooks-empty-file 
11.04.13Human physiotherapy studies9 kBblankinapplication/pdfehdn-2012-busse-empty-file 
11.04.13Short Communications I: 'Scientific Presentations: 10’ and 5’ questions – selected from submissions' 33blankintext/x-cms-noteShort-Communications-I 
11.04.13Default-mode network changes in preclinical Huntington´s disease9 kBblankinapplication/pdfehdn-2012-orth-empty-file 
11.04.13Longitudinal functional and connectivity changes during working memory performance in HD9 kBblankinapplication/pdfehdn-2012-georgiou-karistianis-empty-f... 
11.04.13Better global and cognitive functioning for choreatic compared to hypokinetic- rigid HD9 kBblankinapplication/pdfehdn-2012-t-hart-empty-file 
11.04.13Critical consideration of the criteria for the motor diagnosis of HD9 kBblankinapplication/pdfehdn-2012-paulsen-empty-file 
11.04.13Plenary Session IV: Keynote presentations33blankintext/x-cms-notePlenary-Session-IV 
11.04.13Update on stem cell research: clinical potentials9 kBblankinapplication/pdfehdn-2012-brundin-empty-file 
11.04.13Cognitive alterations in HD9 kBblankinapplication/pdfehdn-2012-stout-empty-file 
11.04.13Roundup I33blankintext/x-cms-noteRoundup-I 
11.04.13Lessons of the day9 kBblankinapplication/pdfehdn-2012-wild-empty-file 
11.04.13Breakfast teaching courses Sat33blankintext/x-cms-noteBreakfast-teaching-courses-sat 
11.04.13Clinical management of Huntington’s disease9 kBblankinapplication/pdfehdn-2012-nance-empty-file 
11.04.13Differential diagnosis of chorea9 kBblankinapplication/pdfehdn-2012-walker-empty-file 
11.04.13Behavioral assessment and management of behavioral issues9 kBblankinapplication/pdfehdn-2012-anderson-empty-file 
11.04.13Training on HD assessments including HD-CC9 kBblankinapplication/pdfehdn-2012-craufurd-empty-file 
11.04.13Training on HD assessments including HD-CC9 kBblankinapplication/pdfehdn-2012-reilmann-empty-file 
11.04.13Training on HD assessments including HD-CC9 kBblankinapplication/pdfehdn-2012-j-thompson-empty-file 
11.04.13Training on HD assessments including HD-CC9 kBblankinapplication/pdfehdn-2012-quarrell-empty-file 
11.04.13Plenary Session V: ‘Understanding and manipulating the pathogenic process in Huntington’s disease’ 33blankintext/x-cms-notePlenary-Session-V 
11.04.13Huntingtin7.9 MBblankinapplication/pdfehdn-2012-cattaneo 
11.04.13Post-translational modifications of huntingtin9 kBblankinapplication/pdfehdn-2012-saudou-empty-file 
11.04.13Stem cells for basic research on HD1.8 MBblankinapplication/pdfehdn-2012-ellerby 
11.04.13Stem cells for basic research on HD9 kBblankinapplication/pdfehdn-2012-l-thompson-empty-file 
11.04.13Plenary Session VI: Keynote presentations33blankintext/x-cms-notePlenary-Session-VI 
11.04.13Keynote presentations9 kBblankinapplication/pdfehdn-2012-aronin-empty-file 
11.04.13Updates on lowering huntingtin (htt) levels9 kBblankinapplication/pdfehdn-2012-davidson-empty-file 
11.04.13Short communications II: Scientific presentations33blankintext/x-cms-noteShort-communications-II 
11.04.13HDAC4 interacts with huntingtin and HDAC4 reduction decreases cytoplasmic aggregation and rescues synaptic dysfunction in HD mouse models9 kBblankinapplication/pdfehdn-2012-bates-empty-file 
11.04.13Aging pathway and poly-Q neurotoxicity656 kBblankinapplication/pdfehdn-2012-nollen 
11.04.13NeuroNet and its potential for the study of neurodegeneration9 kBblankinapplication/pdfehdn-2012-wanker-empty-file 
11.04.13Phenotyping neural networks in an ovine model of HD9 kBblankinapplication/pdfehdn-2012-perentos-empty-file 
11.04.13Plenary Session VII: ‘Therapeutic development programs in Huntington’s Disease’33blankintext/x-cms-notePlenary-Session-VII 
11.04.13Overview of CHDI drug development programs3.5 MBblankinapplication/pdfehdn-2012-pacifici 
11.04.13Htt lowering: Medtronic-Alnylam/Isis/CHDI9 kBblankinapplication/pdfehdn-2012-mcdonald-empty-file 
11.04.13Sirt1-inhibition: SienaBiotech9 kBblankinapplication/pdfehdn-2012-caricasole-empty-file 
11.04.13PDE-10-inhibition: Pfizer9 kBblankinapplication/pdfehdn-2012-schmidt-empty-file 
11.04.13PDE-4-inhibition: GSK9 kBblankinapplication/pdfehdn-2012-gray-empty-file 
11.04.13Bupropion: ACTION-HD9 kBblankinapplication/pdfehdn-2012-priller-empty-file 
11.04.13PREQUEL EHDN9 kBblankinapplication/pdfehdn-2012-ross-empty-file 
11.04.13Reach2HD PBT29 kBblankinapplication/pdfehdn-2012-stout-empty-file 
11.04.13Dopaminergic stabilization in HD: pridopidine9 kBblankinapplication/pdfehdn-2012-kieburtz-empty-file 
08.04.13Plenary Session VIII: EHDN Business Meeting33blankintext/x-cms-notePlenary-Session-VIII 
08.04.13EHDN Update - EC elections, SBAC elections, Structure of EHDN9 kBblankinapplication/pdfehdn-2012-landwehrmeyer-empty-file 
08.04.13Presentation of the HDYO website2.5 MBblankinapplication/pdfehdn-2012-ellison 
08.04.13Standards of Care9 kBblankinapplication/pdfehdn-2012-rea-empty-file 
08.04.13Roundup II33blankintext/x-cms-noteRoundup-II 
08.04.13Lessons of the day9 kBblankinapplication/pdfehdn-2012-wild-empty-file 
08.04.13Breakfast teaching courses Sun33blankintext/x-cms-noteBreakfast-teaching-courses-sun 
08.04.13Drug discovery and development process9 kBblankinapplication/pdfehdn-2012-kwak-empty-file 
08.04.13Training on HD assessments including HD-CC9 kBblankinapplication/pdfehdn-2012-craufurd-empty-file 
08.04.13Training on HD assessments including HD-CC9 kBblankinapplication/pdfehdn-2012-reilmann-empty-file 
08.04.13Training on HD assessments including HD-CC9 kBblankinapplication/pdfehdn-2012-thompson-empty-file 
08.04.13Training on HD assessments including HD-CC9 kBblankinapplication/pdfehdn-2012-quarrell-empty-file 
08.04.13HD for Basic Scientists9 kBblankinapplication/pdfehdn-2012-landwehrmeyer-empty-file 
08.04.13Common issues/problems/inconsistencies in HD assessments9 kBblankinapplication/pdfehdn-2012-ferreira-empty-file 
08.04.13Plenary Session IX: ‘Tools and outcome to monitor disease progression and response to therapy’33blankintext/x-cms-notePlenary-Session-IX 
08.04.13Brain imaging as a potential marker for HD (PET)9 kBblankinapplication/pdfehdn-2012-varrone-empty-file 
08.04.13MRI as a potential marker for HD971 kBblankinapplication/pdfehdn-2012-scahill 
08.04.13Defining predictors of disease1.9 MBblankinapplication/pdfehdn-2012-tabrizi 
08.04.13New assessment tools (cognitive batteries)9 kBblankinapplication/pdfehdn-2012-bachoud-levi-empty-file 
08.04.13New assessment tools (cognitive batteries)9 kBblankinapplication/pdfehdn-2012-stout-empty-file 
08.04.13REGISTRY and Enroll-HD9 kBblankinapplication/pdfehdn-2012-landwehrmeyer-empty-file 
08.04.13Poster Awards9 kBblankinapplication/pdfehdn-2012-landwehrmeyer-empty-file 
08.04.13Roundup III33blankintext/x-cms-noteRoundup-III 
08.04.13Progress in HD research and HD advocacy: a personal view9 kBblankinapplication/pdfehdn-2012-sabine-empty-file 
08.04.13EHA meeting33blankintext/x-cms-noteEHA-meeting 
08.04.13Falling in love, staying in love89 kBblankinapplication/pdfeha-2012-mol 
08.04.13Oral Presentations33blankintext/x-cms-noteOral-Presentations 
08.04.13Juvenile Huntington's disease662 kBblankinapplication/pdfa03-juvenile-hd 
08.04.13Default-mode network changes in preclinical Huntington’s disease1.5 MBblankinapplication/pdfa04-default-mode-network-changes 
08.04.13Better global and cognitive functioning for choreatic compared to hypokinetic-rigid Huntington’s disease380 kBblankinapplication/pdfa06-better-global-and-cognitive-functi... 
08.04.13Critical consideration of the criteria for the motor diagnosis of Huntington disease387 kBblankinapplication/pdfa07-critical-consideration-criteria-mo... 
08.04.13Defining predictors of disease2.0 MBblankinapplication/pdfa11-induced-pluripotent-stem-cells 

Mapp innehåller 87 dokument.
about us | privacy statement | disclaimer | terms of use